Core Insights - Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for prevalent retinal diseases [2] - The company will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference, with management available for one-on-one meetings [1] Company Overview - Kalaris Therapeutics was founded by Dr. Napoleone Ferrara, known for his research that led to anti-VEGF therapy [2] - The company aims to address major unmet medical needs in retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [2] Event Details - The presentation will take place on December 3, 2025, from 11:30 to 11:55 am ET at Florida Atlantic University, Boca Raton, FL [3] - Matthew Feinsod, Chief Medical Officer, will be the speaker at the event [3]

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November 13, 2025Time ...